Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Cyrille Touzeau et al.|Blood|2022Cited by 25
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01Arthur Bobin, Xavier Leleu, Salomon Manier et al.|Blood|2023Cited by 0
First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.Aurore Perrot, Cyrille Touzeau, Cyrille Hulin et al.|Blood|2025Cited by 0